{"entity":{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","aka":[],"tldr":"Led the proton dose-escalation trial in prostate cancer and the comparative-effectiveness debate over proton therapy.","summary":"Anthony Zietman led PROG 95-09, the randomised trial showing high-dose proton-boosted radiotherapy improves biochemical control in localised prostate cancer, and co-leads the PARTIQoL trial comparing protons with IMRT. He has championed evidence-based adoption of proton therapy, led bladder-preserving trimodality therapy at MGH, and edited the International Journal of Radiation Oncology, Biology, Physics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zietman%20AL%5BAuthor%5D%20prostate%20proton"}],"tags":["radiotherapy","proton","prostate"],"related":[],"cancers":["prostate","urothelial"],"sections":[],"technologies":["proton-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["mgh","astro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ijrobp"],"dependsOn":[],"notes":[],"role":"Jenot and William Shipley Professor of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School","institutionId":"mgh","specialisms":["Prostate radiotherapy","Proton therapy","Dose escalation","Bladder preservation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Zietman%20AL%5BAuthor%5D%20prostate%20proton"}],"papers":[{"title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09","journal":"JCO","year":2010,"doi":"10.1200/JCO.2009.25.8475"},{"title":"Particle therapy at the 'tipping point': an introduction to the Red Journal's special edition","journal":"International Journal of Radiation Oncology, Biology, Physics","year":2016}]},"route":"/people/anthony-zietman/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"}],"institution":[{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/"},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/"}],"journal":[{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/"}],"paper":[{"id":"paper-partiqol-astro-2024","kind":"paper","name":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","route":"/key-papers/paper-partiqol-astro-2024/"}]}}